| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Customized |
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Product name | Thymosin Alpha1 |
| CAS number | 62304-98-7 |
| Molecular formula | C129H215N33O55 |
| Molecular weight | 3108.32 |
| Appearance | White Powder |
| Purity | 99.0% |
| Description | Thymalfasin is a chemically synthesized version of thymosin alpha 1 that is identical to human thymosin alpha 1. Thymosin alpha 1 is an acetylated polypeptide. Thymosin alpha 1 is now approved in 35 developing countries for the treatment of Hepatitis B and C. It is also used to boost the immune response in the treatment of other diseases. Thymalfasin (thymosin-alpha 1) is an immunomodulating agent able to enhance the Thl immune response. In vitro: conjugation of thymalfasin (Tα1) with iRGD preserves the immunomodulatory activity of the drug by increasing the proliferation of mouse spleen lymphocytes. Further, compared with Tα1 treatment, Tα1-iRGD treatment of MCF-7 cells considerably increases the number of cells undergoing apoptosis, resulting in a dose-dependent inhibition of cancer cell growth. [1] In vivo: Thymalfasin has been shown to have efficacy in multiple experimental models of immune dysfunction, mainly, infectious diseases such as hepatitis (woodchuck) and influenza (mouse), and cancer such as melanoma (mouse) and colorectal carcinoma (rat) where thymalfasin has shown antitumor effects. |
){kind=link}